Cell therapy for relapsed or refractory B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests an investigational cell therapy that targets two markers (CD20 and CD19) on your lymphoma cells. It may be an option if your B-cell lymphoma has come back or not responded to prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and have a life expectancy of at least 3 months.
- You must have a type of B-cell lymphoma that is CD20-positive (a protein on cancer cells) and has come back or not responded to at least two prior treatments.
- You need to have at least one tumor that can be measured on a CT scan or PET scan.
- Your blood counts (hemoglobin, neutrophils, and platelets) and organ function (kidney, liver, lung, and blood clotting) must be within certain limits.
- You cannot have active infections, serious heart problems, autoimmune diseases, or certain other medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a new immune cell treatment called AcNK-Sup003 for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to prior therapy. The goal is to see if it is safe and effective.
This trial tests an experimental cell therapy (RJMty19) for people with B-cell non-Hodgkin lymphoma that has come back or not responded to prior treatments. It aims to see if the therapy is safe and effective.
This trial tests a new T-cell therapy (EB103) for people with B-cell non-Hodgkin's lymphoma that has come back or stopped responding to treatment. It aims to see if the therapy is safe and effective.
This trial tests a new cell therapy called CT1190B for people with certain types of B-cell lymphoma that have come back or not responded to at least two prior treatments. It aims to see if this therapy can help control the cancer.
This trial tests an experimental cell therapy called KSVCBD for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to standard treatments. The therapy targets two proteins (CD19 and BCMA) on cancer cells to help the immune system fight the disease.
This trial tests a new treatment for people with B-cell non-Hodgkin lymphoma that has come back after at least two prior treatments. It may help if you've already had rituximab or a similar antibody therapy.
Hear when a new R/R B-NHL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.